Heron Therapeutics Inc vs Paychex, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Paychex, Inc. trades at $112.68 (market cap $40.98B). The key difference: Paychex, Inc. is far larger — about 448.1× Heron Therapeutics Inc's market cap, and Paychex, Inc. pays a 4.13% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | PAYX | |
|---|---|---|
Market Cap | $91.46M | $40.98B |
Sector | Health | Industrials |
52-Week High | $1.96 | $147.99 |
52-Week Low | $0.39 | $85.57 |
Enterprise Value | $189.36M | $44.47B |
Dividend Yield | — | 4.13% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Paychex (PAYX) trades at $115.15, up 0.66% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.32 beating expectations of $1.31, and maintains high profitability with a 27.03% net income margin. Recent developments include dividend declarations and positive small business job growth trends.
Outlook remains positive with steady revenue growth and AI expansion driving future performance, though valuation metrics appear elevated with P/E at 23.39. Key risks include macroeconomic sensitivity to small business hiring and competitive pressures. Analyst consensus is mixed with 63.33% hold ratings and a $110 price target slightly below current levels.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →